Castleman Disease Pathogenesis
Copyright © 2017 Elsevier Inc. All rights reserved..
Castleman disease (CD) describes a group of heterogeneous disorders with common lymph node histopathologic features, including atrophic or hyperplastic germinal centers, prominent follicular dendritic cells, hypervascularization, polyclonal lymphoproliferation, and/or polytypic plasmacytosis. The cause and pathogenesis of the four subtypes of CD (unicentric CD; human herpesvirus-8-associated multicentric CD; polyradiculoneuropathy, organomegaly, endocrinopathy, monoclonal plasma cell disorder, and skin changes [POEMS]-associated multicentric CD; and idiopathic multicentric CD) vary considerably. This article provides a summary of our current understanding of the cause, cell types, signaling pathways, and effector cytokines implicated in the pathogenesis of each subtype.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2018 |
|---|---|
| Erschienen: |
2018 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:32 |
|---|---|
| Enthalten in: |
Hematology/oncology clinics of North America - 32(2018), 1 vom: 29. Feb., Seite 11-21 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Fajgenbaum, David C [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Castleman disease |
|---|
| Anmerkungen: |
Date Completed 04.01.2018 Date Revised 07.03.2018 published: Print Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.hoc.2017.09.002 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM278237908 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM278237908 | ||
| 003 | DE-627 | ||
| 005 | 20231225020108.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2018 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.hoc.2017.09.002 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n0927.xml |
| 035 | |a (DE-627)NLM278237908 | ||
| 035 | |a (NLM)29157613 | ||
| 035 | |a (PII)S0889-8588(17)30142-9 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Fajgenbaum, David C |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Castleman Disease Pathogenesis |
| 264 | 1 | |c 2018 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 04.01.2018 | ||
| 500 | |a Date Revised 07.03.2018 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2017 Elsevier Inc. All rights reserved. | ||
| 520 | |a Castleman disease (CD) describes a group of heterogeneous disorders with common lymph node histopathologic features, including atrophic or hyperplastic germinal centers, prominent follicular dendritic cells, hypervascularization, polyclonal lymphoproliferation, and/or polytypic plasmacytosis. The cause and pathogenesis of the four subtypes of CD (unicentric CD; human herpesvirus-8-associated multicentric CD; polyradiculoneuropathy, organomegaly, endocrinopathy, monoclonal plasma cell disorder, and skin changes [POEMS]-associated multicentric CD; and idiopathic multicentric CD) vary considerably. This article provides a summary of our current understanding of the cause, cell types, signaling pathways, and effector cytokines implicated in the pathogenesis of each subtype | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Review | |
| 650 | 4 | |a Castleman disease | |
| 650 | 4 | |a Cytokine storm | |
| 650 | 4 | |a HHV-8 | |
| 650 | 4 | |a Lymphoproliferative disorder | |
| 650 | 4 | |a POEMS | |
| 650 | 4 | |a TAFRO | |
| 650 | 7 | |a Cytokines |2 NLM | |
| 650 | 7 | |a Neoplasm Proteins |2 NLM | |
| 700 | 1 | |a Shilling, Dustin |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Hematology/oncology clinics of North America |d 1991 |g 32(2018), 1 vom: 29. Feb., Seite 11-21 |w (DE-627)NLM013047507 |x 1558-1977 |7 nnns |
| 773 | 1 | 8 | |g volume:32 |g year:2018 |g number:1 |g day:29 |g month:02 |g pages:11-21 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.hoc.2017.09.002 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 32 |j 2018 |e 1 |b 29 |c 02 |h 11-21 | ||